Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

French drug company Sanofi announced it's discontinuing research and development for its next-generation mRNA flu vaccine.

Zoonotic vaccines form an essential frontier in infectious disease prevention, bridging the gap between human and animal health. Zoonotic diseases, caused ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

An avian flu vaccine contract with Moderna may be suspended, pending review of the contract by the current administration, according to a recent Reuters news story. The vaccine contract was awarded to ...

A new strategy has been developed to prevent and treat tuberculosis using antigen-presenting cells. Professor Shin Sung-jae and Dr. Kim Hong-min's research team at Yonsei University Medical School ...

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the ...

Health and Human Services Secretary Robert F. Kennedy Jr. is targeting the government’s Vaccine Injury Compensation Program, without which manufacturers might cease producing shots. (Eric ...